Jeff Schaffnit Shares Sanofi’s Patient Advocacy Voices Series with Caroline Kruse
Jeff Schaffnit, General Manager and Head of Rare Blood Disorders at Sanofi, shared on LinkedIn:
”Many people living with immune thrombocytopenia (ITP) face a critical hurdle: getting a proper diagnosis.
Caroline Kruse, President and CEO of the Platelet Disorder Support Association – PDSA, and other experts know this challenge well.
Despite the organization’s over 25 years of educating, supporting and advocating for the ITP community, diagnosis remains one of the most critical unmet needs for people living with ITP and other rare blood disorders.
My colleague Eric Racine, PharmD, MBA had the opportunity to speak with Caroline as part of Sanofi’s Patient Advocacy Voices series.
We stand proudly with PDSA and the ITP community in our commitment to raising awareness and supporting people living with ITP.
Watch the full conversation here.”
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 16:44The Evolving Treatment Landscape of Hemophilia: From Factor Replacement to Gene Therapy
-
Aug 11, 2026, 16:34Advancing Hemophilia Care Through Training and Local Capacity Building – WFH
-
Aug 11, 2026, 16:26Sabrina H.: The Spectrum of PF4-Mediated Thrombotic Disorders
-
Aug 11, 2026, 16:17Mandy Lauw: From CRTH Training to Clinical Trials
-
Aug 11, 2026, 16:05Obi Light Ogbonnia: From 52 Years of Living With Sickle Cell to a Global Stage
-
Aug 11, 2026, 15:42Iva Pruner: Hemostasis, Thrombosis, and a Little Death Metal
-
Aug 11, 2026, 15:25Bradley Maron։ The AI Revolution in Cardiovascular Drug Development
-
Aug 11, 2026, 15:10Jared Rice: When a Negative DAT Doesn’t Mean the Alloimmune Risk Is Gone
-
Aug 11, 2026, 14:58Manuel De Jesus: Validating the Future of Point-of-Care Anemia Monitoring